Sartorius AG
XETRA:SRT

Watchlist Manager
Sartorius AG Logo
Sartorius AG
XETRA:SRT
Watchlist
Price: 172.6 EUR -1.93%
Market Cap: 12.9B EUR
Have any thoughts about
Sartorius AG?
Write Note

Sartorius AG
Short-Term Investments

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Sartorius AG
Short-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
Sartorius AG
XETRA:SRT
Short-Term Investments
€31.8m
CAGR 3-Years
28%
CAGR 5-Years
9%
CAGR 10-Years
9%
Carl Zeiss Meditec AG
XETRA:AFX
Short-Term Investments
€18.4m
CAGR 3-Years
27%
CAGR 5-Years
15%
CAGR 10-Years
23%
Stratec SE
XETRA:SBS
Short-Term Investments
€2m
CAGR 3-Years
9%
CAGR 5-Years
15%
CAGR 10-Years
11%
Eckert & Ziegler Strahlen und Medizintechnik AG
XETRA:EUZ
Short-Term Investments
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Siemens Healthineers AG
XETRA:SHL
Short-Term Investments
€238m
CAGR 3-Years
1%
CAGR 5-Years
23%
CAGR 10-Years
N/A
Draegerwerk AG & Co KGaA
XETRA:DRW8
Short-Term Investments
€34.3m
CAGR 3-Years
-19%
CAGR 5-Years
1%
CAGR 10-Years
-2%
No Stocks Found

Sartorius AG
Glance View

Market Cap
11.9B EUR
Industry
Health Care

Sartorius AG, a formidable player in the life sciences industry, has been weaving the fabric of innovation within the biotechnology sector for over a century. Originating in 1870 as a precision mechanics workshop in Göttingen, Germany, the company has blossomed into a global powerhouse in the biopharmaceutical and laboratory equipment market. Central to Sartorius's operations is its focus on providing cutting-edge solutions that streamline lab processes and enhance productivity. By offering essential products like bioreactors and cell culture media, Sartorius plays a pivotal role in accelerating research and production processes for pharmaceutical companies worldwide. Underpinning Sartorius's financial success is its dual-pronged strategy: the Bioprocess Solutions division and the Lab Products & Services division. The Bioprocess Solutions wing caters to the production needs of biopharmaceuticals, delivering equipment and technologies crucial for manufacturing therapies and vaccines. Meanwhile, the Lab Products & Services division offers an array of instruments and consumables pivotal for research and quality control. This strategic alignment allows Sartorius to maintain robust growth by capturing value from both research and industrial production stages in biotech. With a well-orchestrated focus on innovation and expansion, Sartorius has cemented its role as a critical enabler in the biopharmaceutical value chain, continually driving developments that shape the future of medicine.

SRT Intrinsic Value
184.25 EUR
Undervaluation 6%
Intrinsic Value
Price

See Also

What is Sartorius AG's Short-Term Investments?
Short-Term Investments
31.8m EUR

Based on the financial report for Sep 30, 2024, Sartorius AG's Short-Term Investments amounts to 31.8m EUR.

What is Sartorius AG's Short-Term Investments growth rate?
Short-Term Investments CAGR 10Y
9%

Over the last year, the Short-Term Investments growth was -13%. The average annual Short-Term Investments growth rates for Sartorius AG have been 28% over the past three years , 9% over the past five years , and 9% over the past ten years .

Back to Top